Dr. Wolfram E. Samlowski, MD
Hematology & Oncology (Hematology & Oncology Physician)
2050 Pinto Ln Ste 200
Las Vegas, NV 89106
Who else practices at this address →
Clark County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Ohio State University College of Medicine (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 735
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: Ohio State University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NV license 12318 · UT license 166160-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Nevada Oncology Specialists Toy Goodman Samlowski PC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 735
- Services billed
- 180,584
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 20,761 | 17 |
| Injection, pembrolizumab, 1 mg | 14,601 | 31 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 9,200 | 11 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 9,180 | 12 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 6,800 | 64 |
| Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg | 6,722 | 13 |
| Injection, fosaprepitant, 1 mg | 6,000 | 19 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 1,760 | 12 |
| Injection, denosumab, 1 mg | 1,680 | 17 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,350 | 61 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Las Vegas, NV | 93 |
| Prednisone Other prescribers in Las Vegas, NV | 91 |
| Gabapentin Other prescribers in Las Vegas, NV | 54 |
| Ondansetron Odt (ondansetron) Other prescribers in Las Vegas, NV | 42 |
| Eliquis (apixaban) Other prescribers in Las Vegas, NV | 29 |
| Venclexta (venetoclax) | 27 |
| Oxycodone Hcl Other prescribers in Las Vegas, NV | 25 |
| Xarelto (rivaroxaban) Other prescribers in Las Vegas, NV | 21 |
| Anastrozole Other prescribers in Las Vegas, NV | 21 |
| Alprazolam Other prescribers in Las Vegas, NV | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 48 payments worth $30,412 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $27,755 |
|---|---|
| Merck Sharp & Dohme LLC | $1,945 |
| Daiichi Sankyo Inc. | $290 |
| Immunocore Limited | $140 |
| Tempus Ai, Inc | $84.32 |
| Pfizer Inc. | $28.08 |
| Novartis Pharmaceuticals Corporation | $24.94 |
| AbbVie Inc. | $23.51 |
| Compensation for services other than consulting (speaking, faculty) | $27,285 |
|---|---|
| Consulting Fee | $1,920 |
| Food and Beverage | $1,133 |
| Travel and Lodging | $73.78 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. May 6, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $3,708 |
| Merck Sharp & Dohme LLC Dec 17, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,920 |
| Regeneron Healthcare Solutions, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,329 |
| Regeneron Healthcare Solutions, Inc. Oct 21, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to HENDERSON, NV · in-kind | $25.90 |
| Regeneron Healthcare Solutions, Inc. Jun 13, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to LAS VEGAS, NV · in-kind | $21.00 |
| Regeneron Healthcare Solutions, Inc. May 9, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to LAS VEGAS, NV · in-kind | $14.00 |
All 11 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 17, 2025 | Consulting Fee KEYTRUDA · ONCOLOGY Company’s descriptionPayment made to Third Party Organization not to Physician. Provided as part of a clinical research engagement. | $1,920 |
| Regeneron Healthcare Solutions, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $1,329 |
| Regeneron Healthcare Solutions, Inc. Oct 21, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to HENDERSON, NV · in-kind | $25.90 |
| Regeneron Healthcare Solutions, Inc. Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. Jun 13, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to LAS VEGAS, NV · in-kind | $21.00 |
| Regeneron Healthcare Solutions, Inc. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $3,708 |
| Regeneron Healthcare Solutions, Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. May 9, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to LAS VEGAS, NV · in-kind | $14.00 |
| Regeneron Healthcare Solutions, Inc. May 6, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,562 |
| Regeneron Healthcare Solutions, Inc. Mar 25, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to LAS VEGAS, NV · in-kind | $12.88 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $4,918 in research payments for these studies, mostly to the institutions running them.
- A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.